Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 1/2016

01-01-2016 | Breast Cancer (B Overmoyer, Section Editor)

The Epidemiology of Male Breast Cancer

Authors: Raina M. Ferzoco, Kathryn J. Ruddy

Published in: Current Oncology Reports | Issue 1/2016

Login to get access

Abstract

Male breast cancer is a rare disease, accounting for only 1 % of breast cancer diagnoses in the USA. The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. In this manuscript, we will review known and possible risk factors for male breast cancer, as well as describe the clinical patterns of the disease.
Literature
1.
2.
Jepson AS, Fentiman IS. Male breast cancer. Int J Clin Pract. 1998;52(8):571–6.PubMed
3.
4.
Society, A.C. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
5.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). SEER cancer statistics review, 1975–2011. Bethesda, Maryland: National Cancer Institute.
6.••
Cardoso F, Bartlett J, Giordano S, et al., Characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program, in 2014 San Antonio Breast Cancer Symposium 2014, European Organization for Research and Treatmento of Cancer: San Antonio, Texas. This study is the largest collection of male breast cancer biologic samples and clinical characteristics to date. All clinical data and pathology were centrally reviewed for 1473 eligible patients who were treated from 1990 to 2010. The authors report on clinical characteristic and overall survival in male breast cancer patients.
7.
Goss PE et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629–39.CrossRefPubMed
8.•
Masci G et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015;20(6):586–92. In this study, Masci et al. evaluated the cliniopathologic characteristics of 97 male breast cancer specimens and found substantial differences than what it typically seen in female breast cancer. Male breast cancer showed higher rates of hormone receptor positivity and lower rates of HER2 overexpression. Furthermore, higher proliferative index and higher grade were associated with shorter overall survival. CrossRefPubMed
9.
Gnerlich JL et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837–44.PubMedCentralCrossRefPubMed
10.
Chung HC et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J. 1991;32(2):126–30.CrossRefPubMed
11.
Fox SB et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol. 1992;166(1):13–8.CrossRefPubMed
12.
Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 1992;5(6):621–5.
13.
Anderson WF et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(2):232–9.CrossRef
14.
Arslan UY et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.CrossRefPubMed
15.
16.
17.
Willsher PC et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17(3C):2335–8.PubMed
18.
Leone JP et al. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601–9.CrossRefPubMed
19.
Anderson WF et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77–86.CrossRefPubMed
20.
Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge Jr GW. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol (Meet Abstr). 2009;27:549.
21.
Jamy O et al. Male breast cancer: a 24 year experience of a tertiary care hospital in Pakistan. Asian Pac J Cancer Prev APJCP. 2015;16(4):1559–63.CrossRefPubMed
22.
Albasri A et al. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia. Saudi Med J. 2014;35(12):1489–93.PubMedCentralPubMed
23.
24.
Tawil AN et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18(1):65–8.CrossRefPubMed
25.
26.
Miao H et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4381–6.CrossRef
27.
28.
Sineshaw HM et al. Black/White disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(21):2337–44.CrossRef
29.
O’Malley CD et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94(11):2836–43.CrossRefPubMed
30.
Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2002;11(3):253–63.CrossRef
31.
Ewertz M et al. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.CrossRefPubMed
32.
Lenfant-Pejovic MH et al. Risk factors for male breast cancer: a Franco-Swiss case–control study. Int J Cancer. 1990;45(4):661–5.CrossRefPubMed
33.
34.
35.
Rosenblatt KA et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83(12):849–54.CrossRefPubMed
36.
Casagrande JT et al. A case–control study of male breast cancer. Cancer Res. 1988;48(5):1326–30.PubMed
37.
Basham VM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res BCR. 2002;4(1):R2.CrossRefPubMed
38.
Ottini L et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63(2):342–7.PubMed
39.
Boyd J et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999;53(1):87–91.CrossRefPubMed
40.
41.
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1434–43.CrossRef
42.
43.
Couch FJ et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13(1):123–5.CrossRefPubMed
44.
Friedman LS et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.PubMedCentralPubMed
45.
46.
47.
Kwiatkowska E et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(12):4452–9.
48.
Thorlacius S et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079–84.PubMedCentralPubMed
49.
50.
Sverdlov RS et al. Genetic analyses of male breast cancer in Israel. Genet Test. 2000;4(3):313–7.CrossRefPubMed
51.
Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433–9.CrossRefPubMed
52.
Meijers-Heijboer H et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–9.CrossRefPubMed
53.
Neuhausen S et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004;108(3):477–8.CrossRefPubMed
54.
Falchetti M et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat. 2008;110(1):161–7.CrossRefPubMed
55.
Martinez-Bouzas C et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat. 2007;103(1):111–3.CrossRefPubMed
56.
Caligo MA et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat. 2004;24(1):100–1.CrossRefPubMed
57.
Weischer M et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):57–63.CrossRef
58.
Rizzolo P et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(8):viii75–82.
59.
60.
61.
Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471–9.CrossRefPubMed
62.
Hultborn R et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293–7.PubMed
63.
Newman J. Breast cancer in men and mammography of the male breast. Radiol Technol. 1997;69(1):17–28. quiz 29–36.PubMed
64.
Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand A Pathol. 1973;81(3):352–8.
65.
Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer. 1999;86(5):744–6.CrossRefPubMed
66.
Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37(4):246–51.CrossRefPubMed
67.
Thomas DB et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135(7):734–48.PubMed
68.
Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125–30.CrossRefPubMed
69.
70.
Brinton LA et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465.PubMedCentralCrossRefPubMed
71.
Hsing AW et al. Risk factors for male breast cancer (United States). Cancer Causes Control CCC. 1998;9(3):269–75.CrossRefPubMed
72.
Brinton LA et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2041–50.CrossRef
73.
Longcope C et al. Estrogen and androgen dynamics in liver disease. J Endocrinol Investig. 1984;7(6):629–34.CrossRef
74.
Guechot J et al. Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer. 1988;62(4):760–2.CrossRefPubMed
75.
Sorensen HT et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93(2):231–3.CrossRefPubMed
76.
77.
Goudie BM et al. Breast cancer in women with primary biliary cirrhosis. Br Med J. 1985;291(6509):1597–8.CrossRef
78.
Wolke AM et al. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med. 1984;76(6):1075–8.CrossRefPubMed
79.
Floreani A et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999;29(5):1425–8.CrossRefPubMed
80.
Rubino A, Fissi S, Secreto G. Bilateral breast cancer in a male patient with hepatocellular carcinoma. A case report. Ann Ital Chir. 2008;79(2):117–9.PubMed
81.
Yoneda S et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol. 2000;95(2):556–7.PubMed
82.
Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53(4):538–49.CrossRefPubMed
83.
Thomas E. Original research: men’s awareness and knowledge of male breast cancer. Am J Nurs. 2010;110(10):32–7. 39–40; quiz 41–2.CrossRefPubMed
84.
Thomas DB et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control CCC. 1994;5(1):9–14.CrossRefPubMed
85.
Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74(2):371–5.PubMed
86.
Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med. 2001;39(3):276–85.CrossRefPubMed
87.
88.
Bove FJ et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. Environ Health Glob Access Sci Sour. 2014;13:68.
89.
90.
Feychting M et al. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology. 1998;9(4):392–7.CrossRefPubMed
91.
Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case–control study. Cancer Causes Control CCC. 1997;8(2):184–91.CrossRefPubMed
92.
Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337(8743):737.CrossRefPubMed
93.
Theriault G et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970–1989. Am J Epidemiol. 1994;139(6):550–72.PubMed
94.
Guenel P et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Ind Med. 1993;50(8):758–64.PubMedCentralPubMed
95.
Stalsberg H et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control CCC. 1993;4(2):143–51.CrossRefPubMed
96.
Wick MR et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111(1):59–69.PubMed
Metadata
Title
The Epidemiology of Male Breast Cancer
Authors
Raina M. Ferzoco
Kathryn J. Ruddy
Publication date
01-01-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 1/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-015-0487-4

Other articles of this Issue 1/2016

Current Oncology Reports 1/2016 Go to the issue

Gastrointestinal Cancers (J Meyer, Section Editor)

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors

Palliative Medicine (A Jatoi, Section Editor)

State of the Art Antiemetic Therapy for Cancer Patients

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer

Melanoma (RJ Sullivan, Section Editor)

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma

Leukemia (A Aguayo, Section Editor)

Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

Gastrointestinal Cancers (J Meyer, Section Editor)

Robotic Surgery for Colon and Rectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits